David Williams to Join INOVIQ Board
David Williams to Join INOVIQ Board
INOVIQ Limited (ASX: IIQ) has announced the appointment of David Williams as a Non-Executive Director and Chairman Elect, effective from the Annual General Meeting (AGM) scheduled for 29 November 2023. Mr Williams will succeed Dr Geoffrey Cumming, who has served as Chairman since the acquisition of Sienna Cancer Diagnostics in July 2020. Dr Cumming will continue to play a vital role on the board as a Non-Executive Director.
董事有限公司(澳交所股票代码：IIQ)已宣布委任David为董事非执行董事及候任主席，由定于2023年11月29日举行的股东周年大会起生效。威廉姆斯将接替杰弗里·卡明博士，后者自2020年7月收购西耶纳癌症诊断公司以来一直担任董事长。作为董事的非执行董事，卡明博士将继续在董事会发挥至关重要的作用。
David Williams is an experienced director and investment banker with a track record in business development, mergers and acquisitions, and capital raising. He has extensive experience advising ASX-listed companies in the food, medical device and pharmaceutical sectors. Currently, Mr Williams serves as Chairman of PolyNovo (ASX:PNV) and RMA Global (ASX:RMY), and is the Managing Director of corporate advisory firm Kidder Williams.
David·威廉姆斯是一位经验丰富的董事和投资银行家，在业务开发、并购和融资方面有过往记录。他在食品、医疗器械和制药行业为澳大利亚证券交易所上市公司提供咨询服务方面拥有丰富的经验。目前，威廉姆斯先生是PolyNovo(澳交所股票代码：PNV)和RMA Global(澳交所股票代码：RMY)的董事长，也是企业咨询公司Kidder Williams的董事董事总经理。
Mr Williams said, "I am excited by the opportunity to assist INOVIQ to move from Research and Development to bringing its exosome and precision diagnostic solutions into the hands of clinicians for patients. I am passionate about technologies that have a positive impact on the lives of patients. Even better if the technology can be a platform and building block for other technologies. INOVIQ has multiple synergistic technologies and a strong internal team with robust external collaborations. A focus on getting the technology to market quickly while developing the platform for other indications will reward shareholders."
威廉姆斯表示：“我很高兴有机会帮助INOVIQ从研发转向将其外显体和精确诊断解决方案带到临床医生手中，为患者服务。我对对患者生活有积极影响的技术充满热情。如果该技术可以成为其他技术的平台和基石，那就更好了。INOVIQ拥有多项协同技术和强大的内部团队，并与强大的外部合作。专注于将技术迅速推向市场，同时开发用于其他适应症的平台将会回报股东。”
Shares in INOVIQ closed 0.79 per cent higher at 64 cents.
INOVIQ股价收盘上涨0.79%，至0.64美元。
Image from The Market Herald.
图片来自《市场先驱报》。
